Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – NETs and endocrine tumours

2402 - Registrational Results of LOXO-292 in Patients with RET-Altered Thyroid Cancers

Date

29 Sep 2019

Session

Proffered Paper – NETs and endocrine tumours

Presenters

Lori Wirth

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

L.J. Wirth1, E. Sherman2, A. Drilon3, B.J. Solomon4, B. Robinson5, J. Lorch6, C. McCoach7, J.D. Patel8, S. Leboulleux9, F. Worden10, T.K. Owonikoko11, M.S. Brose12, M.H. Taylor13, A. Italiano14, O. Gautschi15, M. Garcia16, S..M. Rothenberg17, V. Subbiah18, M. Shah19, M. Cabanillas20

Author affiliations

  • 1 Medical Oncology, Massachusetts General Hospital, Harvard Medical School, 02114 - Boston/US
  • 2 Head And Neck Cancer, Memorial Sloan Kettering Cancer Center, 10038 - New York/US
  • 3 Head And Neck Cancer, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 4 Oncology, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 5 Oncology, Royal North Shore Hospital, 2065 - St. Leonards/AU
  • 6 Oncology, Dana-Farber Cancer InstituteOncology, 02115 - Boston/US
  • 7 Thoracic Medical Oncology, University of California, 94115 - San Francisco/US
  • 8 Thoracic Oncology, University of Chicago, 60637 - Chicago/US
  • 9 Nuclear Medicine, Gustave Roussy, 94800 - VILLEJUIF/FR
  • 10 Head And Neck Oncology, University of Michigan, 48109 - Ann Arbor/US
  • 11 Head And Neck Cancer, Emory University School of Medicine, 30322 - Atlanta/US
  • 12 Otorhinolaryngology, Head And Neck Surgery, University of Pennsylvania- Clinical Research Building, 19104 - Philadelphia/US
  • 13 Knight Cancer Institute - Northwest Portland, Oregon Health & Science University, 97210 - Portland/US
  • 14 Department Of Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 15 Oncology, Cantonal Hospital Luzern and Swiss Group for Clinical Cancer Research, 6000 - Luzern/CH
  • 16 Oncology, Aix Marseille Université, Marseille/FR
  • 17 Research And Development, Loxo Oncology, 06901 - Stamford/US
  • 18 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 19 Medical Oncology, The Ohio State University, 43210 - Columbus/US
  • 20 Endocrine Neoplasia And Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2402

Background

To date, no targeted therapy is approved for patients with RET-altered cancers. LOXO-292 is a highly selective RET inhibitor with activity across known oncogenic RET fusions and mutations. Based on initial data from LIBRETTO-001, LOXO-292 received FDA Breakthrough Designation for the treatment of RET fusion+ non-small cell lung cancer (NSCLC), RET fusion+ thyroid cancer and RET-mutant medullary thyroid cancer (MTC).

Methods

The LIBRETTO-001 global phase I/II study (87 sites, 16 countries) enrolled patients with advanced RET fusion+ cancers and RET-mutant MTC (NCT03157128). LOXO-292 was dosed orally in 28-day cycles. Phase I established the RP2D. Phase II enrolled patients in one of six cohorts based on tumor type, RET alteration and prior therapy. The primary endpoint was ORR. Secondary endpoints included DoR, PFS and OS.

Results

As of 17-June 2019, 253 RET-altered thyroid cancer patients (n = 226 RET-mutant MTC, n = 27 RET fusion+ thyroid cancer) were treated. The primary analysis set (PAS) for LOXO-292 registration in MTC, defined with the US FDA, consisted of the first 55 consecutively enrolled RET-mutant MTC patients who received prior cabozantinib and/or vandetanib. Among these previously treated RET-mutant MTC PAS patients, the investigator-assessed ORR was 56% (95% CI 42-70%, n = 31/55, 2 PRs pending confirmation), including 3 patients with a RET V804M/L gatekeeper mutation (1 CR, 2 PR, all confirmed). Median DoR has not been reached (6 DoR events, 95% CI 11.1 months-NE) with median follow-up of 10.6 months. Biochemical response rates (≥50% decrease lasting ≥4 weeks) were 91% for calcitonin (n = 49/54) and 64% for CEA (n = 34/53). The ORR in evaluable RET fusion+ thyroid cancer patients was 62% (95% CI 41-80%, n = 16/26, 2 PRs pending confirmation). In the safety data set of 531 patients, 5 treatment-related AEs occurred in ≥ 15% of patients: dry mouth, diarrhea, hypertension, increased AST and increased ALT. Most AEs were grade 1-2. Only 9 of 531 (1.7%) patients discontinued LOXO-292 for treatment-related AEs.

Conclusions

LOXO-292 had marked antitumor activity in RET-altered thyroid cancer and was well tolerated. These data will form the basis of an FDA new drug application in late 2019.

Clinical trial identification

NCT03157128.

Editorial acknowledgement

Legal entity responsible for the study

Loxo Oncology.

Funding

Loxo Oncology.

Disclosure

L.J. Wirth: Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merck. E. Sherman: Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: COTA consulting; Advisory / Consultancy: Novartis; Advisory / Consultancy: Goldilocks; Advisory / Consultancy: Eisai; Advisory / Consultancy: Bristol-Myers Squibb. A. Drilon: Advisory / Consultancy: Ignyta; Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: TP therapeutics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Takeda/Ariad/Millenium; Advisory / Consultancy: Helsinn; Advisory / Consultancy: Beigene; Advisory / Consultancy: BergenBio; Advisory / Consultancy: Hengrui Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Bayer; Advisory / Consultancy: Tyra Biosciences; Advisory / Consultancy: Verastem; Advisory / Consultancy: MORE Health; Advisory / Consultancy: Lilly; Research grant / Funding (institution): GlaxoSmithKlein; Research grant / Funding (institution): Teva. B. Robinson: Speaker Bureau / Expert testimony: Loxo Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Leadership role, Shareholder / Stockholder / Stock options: MaynePharma; Leadership role, Shareholder / Stockholder / Stock options: Cochlear; Research grant / Funding (institution): National Health and Medical Reasearch Council. J. Lorch: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Takeda; Speaker Bureau / Expert testimony: Genentech; Research grant / Funding (institution): Bristol-Myer Squibb. C. McCoach: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novaritis; Research grant / Funding (institution): Revolution Medicines; Honoraria (self): Guardant Health; Travel / Accommodation / Expenses: Loxo oncology; Honoraria (self): Takeda. J.D. Patel: Advisory / Consultancy: AbbVie; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Takeda. S. Leboulleux: Speaker Bureau / Expert testimony: Loxo Oncology; Speaker Bureau / Expert testimony: Eisai; Speaker Bureau / Expert testimony: Sanofi. F. Worden: Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self): Cue Pharmaceuticals; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Loxo Oncology; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Pfizer. T.K. Owonikoko: Advisory / Consultancy, Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Astellas Pharma; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Stem CentRx; Research grant / Funding (institution): Regeneron; Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): G1 Therapeutics; Research grant / Funding (institution): Bristol-Myers; Research grant / Funding (institution): Corvus Pharmaceuticals; Research grant / Funding (institution): United Therapeutics; Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): Loxo/Lilly; Research grant / Funding (institution): Fujifilm; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Leadership role, Shareholder / Stockholder / Stock options: Cambium Oncology; Research grant / Funding (institution): Biotherapeutics; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Merck . M.S. Brose: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): Loxo; Advisory / Consultancy: Progenics. M.H. Taylor: Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai Inc; Advisory / Consultancy: Bayer; Advisory / Consultancy: Array Biopharma; Advisory / Consultancy: Blueprint; Advisory / Consultancy: Loxo oncology; Advisory / Consultancy: Novartis; Advisory / Consultancy: Arqule. A. Italiano: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Epizyme; Advisory / Consultancy: ImmuneDesign; Advisory / Consultancy: Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pharmamar. S..M. Rothenberg: Full / Part-time employment: Loxo Oncology. V. Subbiah: Research grant / Funding (institution): Loxo oncology; Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Nanocarrier; Research grant / Funding (institution): Vegenics; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Northwest Biotherapeutics; Research grant / Funding (institution): Berghealth; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Fujifilm; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pharmamar; Research grant / Funding (institution): D3; Research grant / Funding (institution): Pfizer; Travel / Accommodation / Expenses: Astrazeneca; Travel / Accommodation / Expenses: Apollo Hospitals; Licensing / Royalties: Sathgen Biotech; Travel / Accommodation / Expenses: ASCO; Travel / Accommodation / Expenses: ESMO; Research grant / Funding (institution): Blueprint. M. Cabanillas: Speaker Bureau / Expert testimony: Loxo; Advisory / Consultancy: Bayer; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Genentech; Advisory / Consultancy: Eisai; Advisory / Consultancy: Exelixis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.